Fundraising FoxNuvOx Therapeutics
Tucson, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into NuvOx Therapeutics
Sign up to see every warm intro you have to NuvOx Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NuvOx Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
Founders & leadership
NuvOx Therapeutics was founded in 2022 by Evan Unger.
EU
Evan UngerCo-Founder and Executive ChairmanEvan Unger is a board-certified radiologist and Professor Emeritus of Medical Imaging at the University of Arizona with expertise in minimally invasive imaging techniques and contrast media research. He holds over 120 US patents and previously founded a company acquired by DuPont; he currently serves as Executive Officer and Director of NuvOx Therapeutics.
RW
Rong WangPresident and CEORong Wang has held executive positions across Fortune 500 companies and investor-backed firms, with experience in strategy execution and stakeholder management across multiple organizations.
JJ
Jennifer JohnsonChief Operating OfficerJennifer Johnson holds a Ph.D. in Pharmaceutics and Drug Design from the University of Arizona and brings over 20 years of experience in pharmaceutical research, regulatory affairs, and quality systems, including submissions to the FDA and international regulators. She has led R&D and regulatory teams and holds multiple patents in formulation design and drug delivery.
Board
MJ
Marvin J. SlepianBoard director
RC
Richard CarmonaBoard director
JT
Jonathan T. SchillingBoard director
JS
Jon SaxeBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 2 rounds · 2023–2024
▶$235KraisedNov 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$235KraisedNov 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marvin J. SlepianDirector
- Richard CarmonaDirector
- Jonathan T. SchillingDirector
- Jon SaxeDirector
- Rong WangExecutive Officer
- Evan UngerExecutive Officer, Director
- Jennifer JohnsonExecutive Officer
- Offering amount
- $7M
- Amount sold
- $235K
- Minimum investment
- $35K
- Sales commissions
- $405.9K
- Placement agents
- Donald Capital, LLC
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2023 · 2 investors · Other Health CareRule 506(b)
▶$1.1MraisedFeb 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jon SaxeDirector
- Marvin SlepianDirector
- Richard CarmonaDirector
- Rong WangExecutive Officer
- Evan C UngerExecutive Officer, Director
- Jonathan SchillingDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Renovo RxRenovoRx is a life sciences company developing targeted drug delivery for cancer treatment, including its TAMP therapy approach. It operates as a publicly listed biopharmaceutical/medical device company focused on oncology.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
NuvalentNuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies. Its team spans chemistry, biology, translational and clinical development, and commercial functions supporting cancer drug programs.
Companies working in the same space as NuvOx Therapeutics.
In the news
Frequently asked questions
- What does NuvOx Therapeutics do?
- NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
- Who founded NuvOx Therapeutics?
- NuvOx Therapeutics was founded by Evan Unger in 2022.
- Who are NuvOx Therapeutics's investors?
- NuvOx Therapeutics's investors include Pasadena Angels.
- How much funding has NuvOx Therapeutics raised?
- NuvOx Therapeutics has disclosed $1.3M raised across 2 rounds.
- Where is NuvOx Therapeutics headquartered?
- NuvOx Therapeutics is headquartered in Tucson, US.